FEMY is trading 9.1% down at $3.71 in pre-market, extending recent volatility after last week’s sharp swings despite a lack of new company-specific news.
- The move does not appear tied to any earnings or analyst actions released overnight.
- The price action likely reflects speculative trading in a thinly traded micro-cap biotech against a weaker broader market backdrop.